Fang JJ, Huang Q, Shi CL, Tao J, Yan BQ, Gai L, Li XG. Effect of probiotics plus antibiotics on inflammatory cytokines and quality of life in patients with non-biliary severe acute pancreatitis.
Shijie Huaren Xiaohua Zazhi 2018;
26:270-275. [DOI:
10.11569/wcjd.v26.i4.270]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM
To investigate the effect of probiotics plus antibiotics on inflammatory cytokines and the quality of life in patients with non-biliary severe acute pancreatitis (SAP).
METHODS
A total of 68 patients with non-biliary SAP treated from December 2013 to September 2017 at our hospital were selected and divided into a control group (n = 34) and a study group (n = 34). Both groups were given routine intervention and antibiotics (ceftriaxone + ornidazole + gentamycin), and the study group was additionally given probiotics (Bifidobacterium triple live bacteria). Both groups were treated for 7 d. The improvements of symptoms (time for blood amylase back to normal, time for body temperature back to normal, time to abdominal pain remission, and time to anal exhaust), hospitalization time, serum levels of calcitonin (PCT), C reactive protein (CRP), and interleukin-6 (IL-6) at admission and after treatment, quality of life (SF-36) score, and the incidence of adverse reactions were statistically compared between the two groups.
RESULTS
Time for blood amylase back to normal, time for body temperature back to normal, time to abdominal pain remission, and hospitalization time were significantly shorter in the study group than in the control group (P < 0.05). Before treatment, there was no significant difference in the levels of serum PCT, CRP, or IL-6 between the two groups. After treatment, the levels of serum PCT, CRP, and IL-6 in both groups were significantly lower than those before treatment, and the decrease was significantly greater in the study group than in the control group (P < 0.05). There was no significant difference between the two groups in SF-36 score before treatment. After treatment, the SF-36 scores in both groups were significantly higher than those before treatment, and SF-36 score in the study group was significantly higher than that in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group (14.71% vs 8.82%, P > 0.05).
CONCLUSION
Probiotics combined with antibiotics in the treatment of non-biliary SAP patients can effectively relieve clinical symptoms, shorten hospitalization time, reduce serum inflammatory cytokine levels, alleviate the inflammatory response in the body, and improve patients' quality of life, without increasing the risk of adverse reactions.
Collapse